pipeline-prospector-insert-v1
X

Find Ophthalmology Drugs in Phase III Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bevacizumab

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: BioLexis Pte. Ltd

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 28, 2020

            Details:

            Outlook Therapeutics signed agreement with BioLexis Pte. Ltd to better align the interests of all parties with common stockholders of the Company and to help ONS-5010's continuing development.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Reproxalap

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 21, 2020

            Details:

            The INVIGORATE Trial, which will enroll approximately 120 patients aims to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared with vehicle using an allergen chamber.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Loteprednol Etabonate

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 15, 2020

            Details:

            If approved, Kala plans to commercialize KPI-121 0.25% under the brand name EYSUVISâ„¢.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Emixustat Hydrochloride

            Therapeutic Area: Ophthalmology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2020

            Details:

            This publication supports the rationale for investigating emixustat in the treatment of Stargardt disease and diabetic retinopathy.